Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted therapies are being investigated as potentially more efficacious and tolerable alternatives for this multiply-relapsing disease. Based on promising activity with rituximab and lenalidomide in previously untre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Ujjani, Chaitra S., Jung, Sin-Ho, Pitcher, Brandelyn, Martin, Peter, Park, Steven I., Blum, Kristie A., Smith, Sonali M., Czuczman, Myron, Davids, Matthew S., Levine, Ellis, Lewis, Lionel D., Smith, Scott E., Bartlett, Nancy L., Leonard, John P., Cheson, Bruce D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123195/
https://ncbi.nlm.nih.gov/pubmed/27697771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-718106
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares